Novo Nordisk launches Wegovy pill as knownwell joins NovoCare network
The Danish drugmaker has launched an oral version of its Wegovy obesity treatment in the US, alongside an expanded NovoCare support programme and the addition of knownwell as a recognised provider.
Novo Nordisk said the introduction of the Wegovy pill is intended to expand patient choice and access to evidence-based obesity treatment, marking a further step in broadening how the therapy can be delivered.
The company said the launch coincides with an expanded NovoCare experience, designed to help patients find trusted healthcare providers, understand insurance coverage and access ongoing support throughout treatment.
knownwell said it has been recognised as a NovoCare provider. The weight-inclusive primary care and metabolic health company offers both virtual and in-person services and will connect patients seeking Food and Drug Administration-approved obesity treatments to its multidisciplinary care model.
Related reading
- PayPal unveils new analytics tools for advertisers at CES
- AMD unveils new Ryzen AI processors and desktop chip
- Longevity boom reshapes investment outlook as ageing populations stay healthier for longer
knownwell said its national hybrid model integrates medical, nutritional and behavioural support, with care led by clinicians who are board-certified in obesity medicine. The company said its approach is designed to support patients beyond prescribing, through personalised treatment plans and ongoing clinical engagement.
Novo Nordisk said the Wegovy pill is intended to widen access for patients who may prefer an oral treatment option, while the expanded NovoCare programme aims to improve navigation of care and long-term treatment support.
The Recap
- Novo Nordisk launched the Wegovy pill as an oral GLP-1 option.
- knownwell recognised as a NovoCare provider for metabolic care.
- Patients seeking Wegovy pill can connect with recognised providers.
